This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Dermatology  • Dermatology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Elaine Siegfried, MD
St Louis, Mo

Arch Dermatol. 2001;137:422.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Tacrolimus is the first T-cell selective immunosuppressive agent with demonstrated topical applications. The Food and Drug Administration recently approved topical tacrolimus ointment with an indication for treating atopic dermatitis in patients as young as age 2 years. In clinical trials, significant absorption did not occur through intact skin and rarely occurred through dermatitic skin. Detectable blood levels diminished as the skin improved. In phase 3 atopic dermatitis trials lasting more than 3 years, reported adverse effects have been minor. Recipes have long been available for compounded formulations similar to the proprietary agent. This case report is another example of compounded tacrolimus ointment used with success for a difficult-to-treat inflammatory cutaneous problem. Other reported uses include pyoderma gangrenosum, cutaneous Crohn disease, and ichthyosis linearis circumflexa. However, uncontrolled enthusiasm for this drug must be tempered with the caution reserved for any medication that has a wide range of systemic . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Successful Treatment of Erosive Lichen Planus With Topical Tacrolimus
Elizabeth V. Lener, Joaquin Brieva, Marianne Schachter, Lee E. West, Dennis P. West, and Rokea A. el-Azhary
Arch Dermatol. 2001;137(4):419-422.
EXTRACT | FULL TEXT